Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation

被引:537
作者
Lowance, D
Neumayer, HH
Legendre, CM
Squifflet, JP
Kovarik, J
Brennan, PJ
Norman, D
Mendez, R
Keating, MR
Coggon, GL
Crisp, A
Lee, IC
机构
[1] Piedmont Hosp, Dept Internal Med, Atlanta, GA 30367 USA
[2] Univ Erlangen Nurnberg, Med Klin, Dept Nephrol, D-8520 Erlangen, Germany
[3] Hop Necker Enfants Malad, Serv Reanimat & Transplantat, Paris, France
[4] Univ Catholique Louvain, Clin Univ St Luc, Dept Transplantat, B-1200 Brussels, Belgium
[5] Univ Clin 3, Dept Nephrol & Dialysis, Vienna, Austria
[6] Hosp Univ Penn, Infect Control Off, Philadelphia, PA USA
[7] Oregon Hlth Sci Univ, Dept Immunogenet, Portland, OR USA
[8] Natl Inst Transplantat, Los Angeles, CA USA
[9] Mayo Clin, Rochester, MN USA
[10] Glaxo Wellcome Res & Dev Ltd, Dept Infect Dis Clin Res, Greenford, Middx, England
[11] Glaxo Wellcome Res & Dev Ltd, Dept Clin Studies, Greenford, Middx, England
关键词
D O I
10.1056/NEJM199905133401903
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV-positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation. Results Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P<0.001) and the seropositive patients (P=0.03). Among the seronegative patients, the incidence of CMV disease 90 days after transplantation was 45 percent among placebo recipients and 3 percent among valacyclovir recipients. Among the seropositive patients, the respective values were 6 percent and 0 percent. At six months, the incidence of CMV disease was 45 percent among seronegative recipients of placebo and 16 percent among seronegative recipients of valacyclovir; it was 6 percent among seropositive placebo recipients and 1 percent among seropositive valacyclovir recipients. At six months, the rate of biopsy-confirmed acute graft rejection in the seronegative group was 52 percent among placebo recipients and 26 percent among valacyclovir recipients (P=0.001). Treatment with valacyclovir also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources. Hallucinations and confusion were more common with valacyclovir treatment, but these events were not severe or treatment limiting. The rates of other adverse events were similar among the groups. Conclusions Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV disease after renal transplantation. (N Engl J Med 1999; 340:1462-70.) (C) 1999, Massachusetts Medical Society.
引用
收藏
页码:1462 / 1470
页数:9
相关论文
共 40 条
  • [1] A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS
    BALFOUR, HH
    CHACE, BA
    STAPLETON, JT
    SIMMONS, RL
    FRYD, DS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) : 1381 - 1387
  • [2] CANDINAS D, 1994, SCHWEIZ MED WSCHR, V124, P1789
  • [3] PRIMARY CYTOMEGALOVIRUS AND OPPORTUNISTIC INFECTIONS - INCIDENCE IN RENAL-TRANSPLANT RECIPIENTS
    CHATTERJEE, SN
    FIALA, M
    WEINER, J
    STEWART, JA
    STACEY, B
    WARNER, N
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 240 (22): : 2446 - 2449
  • [4] CHITWOOD KK, 1993, CLIN TRANSPLANT, V7, P320
  • [5] INVITRO SUSCEPTIBILITY OF CYTOMEGALOVIRUS ISOLATES FROM IMMUNOCOMPROMISED PATIENTS TO ACYCLOVIR AND GANCICLOVIR
    COLE, NL
    BALFOUR, HH
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1987, 6 (03) : 255 - 261
  • [6] CONTI DJ, 1995, ARCH SURG-CHICAGO, V130, P1217
  • [7] Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation - A meta-analysis
    Couchoud, C
    Cucherat, M
    Haugh, M
    Pouteil-Noble, C
    [J]. TRANSPLANTATION, 1998, 65 (05) : 641 - 647
  • [8] COX DR, 1972, J R STAT SOC B, V34, P187
  • [9] A PROSPECTIVE RANDOMIZED STUDY OF ACYCLOVIR VERSUS GANCICLOVIR PLUS HUMAN IMMUNE GLOBULIN PROPHYLAXIS OF CYTOMEGALOVIRUS-INFECTION AFTER SOLID-ORGAN TRANSPLANTATION
    DUNN, DL
    GILLINGHAM, KJ
    KRAMER, MA
    SCHMIDT, WJ
    ERICE, A
    BALFOUR, HH
    GORES, PF
    GRUESSNER, RWG
    MATAS, AJ
    PAYNE, WD
    SUTHERLAND, DER
    NAJARIAN, JS
    [J]. TRANSPLANTATION, 1994, 57 (06) : 876 - 884
  • [10] TREATMENT OF INVASIVE CYTOMEGALOVIRUS DISEASE IN SOLID ORGAN TRANSPLANT PATIENTS WITH GANCICLOVIR
    DUNN, DL
    MAYORAL, JL
    GILLINGHAM, KJ
    LOEFFLER, CM
    BRAYMAN, KL
    KRAMER, MA
    ERICE, A
    BALFOUR, HH
    FLETCHER, CV
    BOLMAN, RM
    MATAS, AJ
    PAYNE, WD
    SUTHERLAND, DER
    NAJARIAN, JS
    [J]. TRANSPLANTATION, 1991, 51 (01) : 98 - 106